Alzheimers Disease Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Detection Technique, By End user, By Region & Competition, 2021-2031F

The Global Alzheimer's Disease Biomarkers Market is projected to expand from USD 0.91 Billion in 2025 to USD 1.43 Billion by 2031, reflecting a compound annual growth rate of 7.82%. These biomarkers function as quantifiable biological indicators found in cerebrospinal fluid, blood plasma, or through imaging techniques, serving to detect pathological alterations such as amyloid beta plaques and tau protein tangles. This growth trajectory is chiefly driven by the increasing global elderly population and the urgent clinical need for early diagnosis to maximize the effectiveness of new therapeutic options. Additionally, the rapid advancement of noninvasive blood-based diagnostic solutions is broadening market reach by reducing the patient burden and procedural invasiveness typical of conventional lumbar punctures.

However, the market faces substantial hurdles regarding the high expense of developing diagnostic assays and the lack of consistent reimbursement coverage, which limits availability in price-sensitive areas. This economic barrier is especially concerning given the rising prevalence of the disease, which demands scalable diagnostic interventions. According to the Alzheimer's Association, an estimated 7.2 million Americans aged 65 and older are expected to be living with Alzheimer's dementia in 2025. This increasing incidence highlights a critical industry need for cost-effective and accessible biomarker platforms to ensure timely patient care and management.

Market Driver

The proliferation of disease-modifying therapies (DMTs) is fundamentally transforming the market by requiring precise companion diagnostics to determine patient eligibility and monitor treatment. As regulatory agencies approve new monoclonal antibodies that target amyloid-beta, clinical protocols are swiftly incorporating biomarker testing to verify amyloid pathology before starting therapy. This connection elevates diagnostics from simple screening tools to essential gatekeepers for pharmaceutical access, directly increasing the volume of FDA-cleared assays. To illustrate the clinical efficacy propelling this demand, Eli Lilly and Company reported in a July 2024 'FDA Approval Press Release' that the Phase 3 TRAILBLAZER-ALZ 2 study, critical for Kisunla's approval, showed the treatment slowed clinical decline by 35% in participants with confirmed amyloid and intermediate tau pathology, necessitating diagnostic platforms capable of detecting these specific markers.

Concurrently, the swift development and commercial release of minimally invasive blood-based biomarkers are removing accessibility obstacles linked to traditional PET scans and cerebrospinal fluid analysis. The adoption of high-performance plasma assays, particularly those detecting phosphorylated tau (p-tau), facilitates affordable prescreening within primary care, effectively triaging patients for further confirmation. This technological evolution is supported by recent data; an article published in 'JAMA Neurology' by the American Medical Association in January 2024 reported that a commercial p-tau217 blood assay achieved 96% diagnostic accuracy in detecting elevated brain amyloid. Such precision encourages widespread adoption, which is crucial given the high financial impact of the condition; the Alzheimer's Association projected that the total national cost for caring for individuals with Alzheimer's and other dementias would reach $360 billion in 2024.

Market Challenge

The growth of the market is primarily hindered by the substantial costs associated with developing diagnostic assays combined with inconsistent reimbursement policies. Manufacturers must invest heavily to validate and manufacture these tests, leading to premium pricing that limits access for numerous healthcare providers and patients. When insurance payers do not offer standardized or sufficient coverage, the financial responsibility falls on the individual or the medical facility. This economic uncertainty creates reluctance within healthcare systems to establish biomarker testing as a routine standard of care, thereby restricting testing volumes and stalling revenue growth for market participants.

This financial strain is especially significant within the broader economic landscape of dementia care, where resources are predominantly directed toward long-term management rather than diagnostics. The struggle for limited healthcare funding complicates the adoption of expensive diagnostic tools in the absence of guaranteed payment structures. According to the Alzheimer's Association, total estimated payments for health care, long-term care, and hospice services for people aged 65 and older with dementia were $360 billion in 2024. This immense existing expenditure on care delivery consumes available budgets, leaving little room for adopting new diagnostic technologies and directly limiting the scalability of the biomarkers market.

Market Trends

The integration of Artificial Intelligence (AI) into biomarker discovery is revolutionizing the market by facilitating the detection of new pathological signatures from intricate, multi-modal datasets. In contrast to traditional single-assay validation, AI algorithms possess the capacity to analyze immense collections of genomic, proteomic, and imaging data to identify subtle, non-linear patterns that exist before clinical symptoms appear. This ability hastens the creation of precision diagnostics by revealing latent biological factors correlated with disease progression, which improves patient stratification for clinical trials. Underscoring the promise of this technological convergence, Premier Science reported in January 2025, within the article 'Revolutionizing Alzheimer's Diagnostics: AI Tool Shows Superior Accuracy Over Traditional Methods', that a novel AI model attained nearly 90% prediction accuracy on independent datasets by recognizing latent metabolic and physiological factors linked to cognitive decline.

At the same time, the rise of digital biomarkers for remote monitoring is establishing a new standard for scalable and accessible patient assessment. This trend shifts diagnostic data capture from invasive clinical settings to continuous, non-intrusive collection utilizing consumer-grade sensors and specialized peripherals to monitor oculomotor, vocal, and behavioral metrics. These digital instruments are especially beneficial for detecting preclinical neurodegenerative changes often missed by episodic clinical examinations, presenting a cost-efficient method for mass population screening. Highlighting the precision of these non-invasive approaches, the University of Strathclyde announced in October 2025 regarding the 'ViewMind Atlas' system that the platform's integration of eye-tracking technology with machine learning analysis achieved a 96% accuracy rate in detecting asymptomatic carriers of a genetic mutation associated with Alzheimer's disease.

Key Market Players

• Enzo Life Sciences Inc.
• Thermo Fisher Scientific Inc.
• AnaSpec Inc.
• Merck KGaA
• Cell Signaling Technology Inc.
• Fujirebio Diagnostics Inc
• 23andMe Inc.
• NanoSomiX Inc.
• QIAGEN NV
• Quest Diagnostics

Report Scope

In this report, the Global Alzheimer's Disease Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alzheimer's Disease Biomarkers Market, By Type

• CSF Biomarkers
• Amyloid Beta
• Tau Protein
• Genetic Biomarkers
• Apolipoprotein E
• Blood Biomarkers
• Others

Alzheimer's Disease Biomarkers Market, By Detection Technique

• Molecular Diagnostics
• Immunoassays

Alzheimer's Disease Biomarkers Market, By End user

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Alzheimer's Disease Biomarkers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alzheimer's Disease Biomarkers Market.

Available Customizations:

Global Alzheimer's Disease Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).